Stockscreener 앱 받기
65.37
1.48%
-0.98
시간 외 거래:
64.03
-1.34
-2.05%
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Insider Sell: Andrew Callos Sells 7,449 Shares of Cytokinetics I - GuruFocus
Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares, retains large stake - Stock Titan
Blum Robert I, president & CEO of Cytokinetics, sells $490k in stock - Investing.com
Director at CYTOKINETICS (CYTK) receives 95-share equity grant in lieu of cash - Stock Titan
Cytokinetics (NASDAQ: CYTK) director receives 95-share equity grant - Stock Titan
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
CYTOKINETICS (NASDAQ: CYTK) director receives 191-share equity grant as retainer - Stock Titan
Cytokinetics EVP Callos sells $491k in stock By Investing.com - Investing.com Canada
Cytokinetics EVP Callos sells $491k in stock - Investing.com
Andrew Callos sells via 10b5-1; CYTK (NASDAQ: CYTK) insider filings - Stock Titan
Cytokinetics Incorporated : Read Our 2025 Report - marketscreener.com
Cytokinetics Highlights MYQORZO Launch Progress, Teases 2026 Phase 3 Readout at Needham Conference - MarketBeat
Cytokinetics Inc stock (US2328281044): Does cardiac muscle therapy execution now define its biotech - AD HOC NEWS
Fed Watch: Is Cytokinetics Incorporated undervalued by DCF analysisSwing Trade & Verified Short-Term Plans - baoquankhu1.vn
CYTK Analyst Rating: Wells Fargo Initiates Overweight April 2026 - Meyka
Cytokinetics Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Q1 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Q3 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock Earnings Transcripts - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock News, Headlines & Updates - GuruFocus
Market Review: What are the future prospects of Cytokinetics IncorporatedAnalyst Downgrade & Real-Time Price Movement Reports - baoquankhu1.vn
Wells Fargo initiates coverage of Cytokinetics (CYTK) with overweight recommendation - MSN
CYTK Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Momentum Shift: Is Cytokinetics Incorporated stock heavily shortedWeekly Profit Analysis & Scalable Portfolio Growth Methods - baoquankhu1.vn
Risk Recap: Will Cytokinetics Incorporated stock go up in YEAR2026 Pullback Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Cytokinetics Inc (HAM:KK3A) Valuation: Possible Value Trap, Think Twice - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock Price, Trades & News - GuruFocus
Who's Buying or Selling Cytokinetics Inc (HAM:KK3A) Stock Today? - GuruFocus
Cytokinetics Inc Stock Operating Data - GuruFocus
Cytokinetics (CYTK) EVP Malik sells $292,985 in stock By Investing.com - Investing.com India
Cytokinetics (CYTK) EVP Malik sells $292,985 in stock - Investing.com
Insider Sell: Fady Malik Sells 4,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $292,985, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (CYTK) EVP nets 4,500-share sale after option exercises - Stock Titan
CYTK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CYTK (NASDAQ: CYTK) insider sale filing lists 22,000-share option exercise - Stock Titan
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance Australia
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Barclays Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - MarketBeat
Barclays Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $95 - Moomoo
Aberdeen Group plc Sells 444,771 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus - Yahoo Finance
Cytokinetics, Incorporated (CYTK) Stock forecasts - uk.finance.yahoo.com
CYTK PE Ratio & Valuation, Is CYTK Overvalued - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
Barclays Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $95 - Moomoo
CYTK SEC FilingsCytokinetics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cytokinetics (CYTK): CEO Blum sells $499k in shares - Investing.com UK
Cytokinetics (CYTK): CEO Blum sells $499k in shares By Investing.com - Investing.com Canada
2.69%
0.25%
자본화:
|
볼륨(24시간):